MAFA
NVO icon

MJT & Associates Financial Advisory’s Novo Nordisk NVO Stock Holding History

MJT & Associates Financial Advisory’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.7K Buy
283
+59
+26% +$2.72K 0.01% 187
2026
Q2 		$10.7K Hold
224
– – 0.01% 192
2026
Q1 		$8.23K Hold
224
– – 0.01% 201
2025
Q4 		$11.4K Hold
224
– – 0.01% 175
2025
Q3 		$12.4K Hold
224
– – 0.01% 170
2025
Q2 		$15.5K Hold
224
– – 0.02% 173
2025
Q1 		$15.6K Buy
+224
New +$18.5K 0.01% 165

Other funds holding NVO

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
MCP
Martin Capital Partners Eugene, Oregon $279M AUM 18.87% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EIA
Eastover Investment Advisors Charlotte, North Carolina $257M AUM 14.8% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return
BFA
Benedict Financial Advisors Atlanta, Georgia $504M AUM 20.67% 1-Year Est. Return
HWA
Heartwood Wealth Advisors Richmond, Virginia $1.27B AUM 11.08% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
RI
Ridgewood Investments Springfield, New Jersey $271M AUM

MJT & Associates Financial Advisory's NVO Position: Q3 2026 in Review

MJT & Associates Financial Advisory increased its Novo Nordisk (NVO) stake by 26% in Q3 2026, buying an estimated $2.72K and bringing the position to 283 shares worth $10.7K. The position accounts for 0.01% of the portfolio, ranked #187.

MJT & Associates Financial Advisory first reported a position in NVO in Q1 2025 and has held it in 7 quarters since. The position peaked at $15.6K in Q1 2025. 64 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • MJT & Associates Financial Advisory held 283 shares of Novo Nordisk worth $10.7K as of Q3 2026.
  • MJT & Associates Financial Advisory bought 59 Novo Nordisk shares in Q3 2026, an estimated $2.72K.
  • Novo Nordisk made up 0.01% of MJT & Associates Financial Advisory's portfolio in Q3 2026, its #187 holding.
  • MJT & Associates Financial Advisory first reported a position in Novo Nordisk in Q1 2025 and has held it in 7 quarters since.
  • MJT & Associates Financial Advisory's Novo Nordisk position peaked at $15.6K in Q1 2025.
  • 64 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on MJT & Associates Financial Advisory's 13F filing for Q3 2026, filed 7 Oct 2026.